Smithers’ Extractables and Leachables USA 2020
2020-10-26 - 2020-10-28 | Virtual Event
Smithers’ 9th annual Extractables and Leachables USA conference is returning. This is a unique event in the extractables and leachables industry, bringing together top companies from the entire supply chain and making it easy to network with peers, leading to new, beneficial connections. The event is a must for the extractables and leachables industry, wherein players need to stay on top of market changes, fluctuating regulations, medical device strategies, and safety standards for consumer safety and product success. Smithers’ E&L 2020 gathers industry experts to discuss these topics, and more. The program consists of two days of industry-leading presentations by over 20 expert speakers, supplemented by valuable networking breaks, an included networking lunch, and a networking reception at the end of day one.
Companies who have attended in the past include B Braun, The FDA, Toxikon, Intertek, Abbott, Nelson Laboratories, Boston Scientific, Vimta, Jordi Labs, VR Analytical, Teknor Apex, and many more.
Visit the event website for more information: https://www.eandl-conference.com/usa.
Contact Producer Ashli Speed, ASpeed@Smithers.com, with questions about the program.
For companies interested in increasing their brand visibility in front of a target market, contact Shannon Siegferth, SSiegferth@Smithers.com, about sponsorship opportunities.
To get the latest updates, follow the event on twitter @SmithersELEvent, join the LinkedIn group Extractables and Leachables Forum, or join the mailing list: https://www.eandl-conference.com/usa/register-interest.

TIGIT Therapies Digital Summit
2020-10-26 - 2020-10-27 | Online
Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies.
Following the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications, a great deal of momentum has built in this competitive space.

However, core challenges must still be addressed by the community, such as:

Investigating the TIGIT pathway, ligands, and modes of action
Optimizing biomarker strategy to identify optimal patient populations and indications
Rationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit

The TIGIT Therapies Digital Summit will gather the greatest minds in TIGIT research in a dedicated, two day meeting. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings for your future research.
In such a fast-paced industry, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact.
Working with leaders in the industry we have developed a meeting that brings together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies.
At a time when we are more isolated than ever, this event will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies.
Head to the TIGIT Therapies Digital Summit website to access your complimentary event guide and find out more!

4th Annual Gene Therapy for Rare Disorders Europe | Running Digitally for 2020
2020-10-26 - 2020-10-28 | Virtual Event
Realise the Commercial Potential of Gene Therapies
The 4th Annual Gene Therapy for Rare Disorders Europe is dedicated to overcoming
manufacturing, clinical, and commercialisation challenges drug developers face when delivering
gene therapies to market.
With new European gene therapy approvals rapidly approaching and investment at an all-time high, the digital meeting will leverage the experience from the first to market pioneers, as well as unveiling the strategies the next generation of drug developers are employing to improve efficacy, safety and commercial viability.

Across three days, we will virtually unite 250+ leading experts from innovative biotechs, large pharmaceutical companies, academia, and key service providers. Understand the nuances of the European regulatory landscape, engage with European payers and ensure your manufacturing and logistical approaches are set for the commercial primetime to come.
Wherever you’re based, if you’re looking to develop and launch gene therapy products in Europe, this is your comprehensive guide to define your commercial path forward
To learn more about Gene Therapy for Rare Disorders Europe please click here: https://ter.li/k19u77

TIGIT Therapies Digital Consortium
2020-10-27 | Online
Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies.
Following the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications, a great deal of momentum has built in this competitive space.

However, core challenges must still be addressed by the community, such as:

Investigating the TIGIT pathway, ligands, and modes of action
Optimizing biomarker strategy to identify optimal patient populations and indications
Rationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit

The TIGIT Therapies Digital Consortium will gather the greatest minds in TIGIT research in a series of monthly, themed seminars. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings with monthly executive summaries and exclusive content after the event.
In such a fast-paced industry, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact.
Working with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies.
At a time when we are more isolated than ever, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies.
Head to the TIGIT Therapies Digital Consortium website to access your complimentary event guide and find out more!

Macrophage-directed Therapies Summit 2020
2020-10-27 - 2020-10-29 | Virtual Event
Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond
With the explosive excitement and clinical proof of concepts utilizing CD47 approaches, macrophage-directed therapies have started to witness interest and investment in novel macrophage targets outside of CD47.

The 2nd Macrophage-directed Therapies Summit is focused on optimizing the potential of macrophage therapies, through direct utilization of cells or small molecule approaches to target and stimulate macrophage cells in vivo for oncological indications and beyond.
Bringing together the leading experts, we will explore the clinical development of CD47 checkpoint blockades, combination strategies, macrophage repolarization approaches and engineered macrophages.
Join the trailblazers of macrophage therapeutic development, from the likes of Carisma Therapeutics, Faron Pharmaceuticals, and Verseau Therapeutic, as we come together to advance the fundamental understanding of macrophage biology, avoiding on-target toxicities and the emerging field of macrophage cellular immunotherapy.

Pharmaceutical Microbiology East Coast
2020-10-28 - 2020-10-29 | Virtual Event
SMi’s 3rd Annual Pharmaceutical Microbiology East Coast
Conference: 28 – 29 October 2020
Location: Virtual Event
Website: www.microbiologyeastcoast.com/PJWL
SPONSORED BY: Associates of Cape Cod, bioMérieux, Bioscience International, C.T.L. MAT, LONZA
CHAIRED BY: Lynne Ensor,VP Technical, Parexel
Exploring the current approaches towards improved contamination control
The pharmaceutical microbiology industry has seen many changes during the progression into the 21st century. With advances in rapid microbiological methods, revisions being made to regulations in the industry, enhanced knowledge of the human microbiome, and novel testing methods, this industry is ever expanding.
Join industry experts to discuss and analyze the latest advances and challenges within the industry. Network with industry professionals, discuss the revision of Annex 1, explore data integrity considerations for conventional and rapid microbiology methods, analyze arising issues with environmental monitoring and gain insight into an industry perspective on automated endotoxin testing and process automation.
Event Hashtag: #SMiPharmaMicroEC
HIGHLIGHTS FOR 2020:

Discuss ongoing complication of personnel derived contaminations from the FDA
Gain valuable insight towards microbiological quality considerations in non-sterile manufacturing and control of BCC from Parexel
Learn from the perspective of the US Pharmacopeia on container closure integrity evaluation
Examine an end-to-end contamination risk assessment for autologous cell therapy from Juno Therapeutics
Explore a back to back Genentech session covering technical considerations for microbial QC of raw materials used in biotechnology and the past, current and future state of Mycoplasma testing

The Use of Recombinant Chromogenic Assays as Alternate Methods for the Bacterial Endotoxins Test (BET)
Workshop Leader:
Veronika Wills, Manager, Technical Services, Associates of Cape Cod
View the full agenda: www.microbiologyeastcoast.com/PJWL
WHO SHOULD ATTEND
Senior Microbiologist, Lead Scientist, Laboratory Manager, QA Specialist, Drug Substance External Manufacturer, QC Scientists, Heads of Quality, Business Development Manager, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeia Scientist, Analytical Standards Specialist
To know more about Pharmaceutical Microbiology East Coast please click here.

Dry AMD Therapeutic Development Summit
2020-10-28 - 2020-10-29 | Virtual Event
Finding new therapeutics to counter the progression of Dry AMD and prevent the geographical atrophy has never been more important. The aging population creates an ever-growing clinical need for next-generation therapeutics.
This action-packed two-day digital agenda holds 22 Presentations from industry and academic leaders, a virtual poster session and 5+ hours of networking, you can join the only platform discussing issues present in the development of Dry AMD therapeutics.

Join this critical global forum which will be uniting industry specialists from pharma, biotechs, academia and solution providers as we target the most pressing issues important to bringing the next generation of Dry AMD drugs to market.
Companies speaking include: Genentech, 4D Molecular Therapeutics, Alkeus Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, University of California, San Francisco, Regenerative Patch Technologies, Novartis, Stealth BioTherapeutics Inc
Find out more here > https://ter.li/mc1pmz

Patient-to-Patient Supply for Cell Immunotherapies Summit
2020-10-29 - 2020-10-30 | Digital Event
Achieving Standardization & Operational Excellence in Vein-to-Vein Supply
As an increasing number of candidates enter the clinic and promise to be a mainstay in the future of cancer treatment, cell therapies pose unique supply chain challenges.

At the inaugural Patient-to-Patient Supply for Cell Immunotherapies Summit, this community will share their expertise and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale.
From time and temperature sensitivity, to patient-facing service and integrated platforms, a seamless vein-to-vein supply chain is central in maintaining cell immunotherapy safety and efficacy at scale and maximizing the patient experience.
Join the strategic experts from GSK, bluebird bio, Adaptimmune, Celgene, BMS and more, to discuss best practice for patient-facing supply chains and build integrated platforms for chain of identity and end-user access.

Digital 5th Neoantigen Based Therapies Summit
2020-11-03 - 2020-11-05 | Online | Digital Event
With all eyes on the explosive neoantigen field watching to see how it can revolutionize cancer immunotherapies and rival the current T cell therapies, it is clear that critical questions still remain to be addressed to ensure full therapeutic success.

Taking place from the comfort of your own home this year, the 5th Neoantigen Based Therapies Summit remains the only industry focused meeting dedicated to the full end-to-end development and commercialization of neoantigen-based cancer immunotherapies.
View the full event guide for more details on this content packed 3-day virtual event.
We’ll be addressing the most pressing challenges in the field, including:

Identifying both personalized and shared Neoantigens to supercharge development of next generation immunotherapy with University of Miami and Netherlands Cancer Institute
Improving prediction accuracy by exploring different neoantigen sources with Ervaxx, Precision Biologics and Broad Institute
How to maximize immunogenicity to drive clinical development & success with Gritstone Oncology, Genocea and Treos Bio
Reducing complex process and release times by navigating through complex manufacturing challenges with Achilles Therapeutics, Vaximm and ISA Therapeutics

Download the official brochure to see what sessions will help you to advance your cancer immunotherapy pipeline.
Join us online to gain the practical insights you need to improve the immune response and commercial viability of your neoantigen based cancer immunotherapy.

8th Microbiome R&D & Business Collaboration Forum: USA
2020-11-05 - 2020-11-06 | San Diego, USA
This forum has a long-standing reputation for bringing together leading academic and industry microbiome researchers. Presentations will feature the latest research into the human microbiome as well as effective business and commercialization strategies for new products.

Topics covered on the agenda include:

IBD, Colitis, and Metabolic Diseases
Gut-brain axis
Women’s health
Skin & Cosmeceuticals
Personalized nutrition
Business Collaboration – Regulations & Investment
Probiotics & Prebiotics
Roundtable discussions

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

2nd Skin Microbiome & Cosmeceuticals Congress: USA
2020-11-05 - 2020-11-06 | San Diego, USA
This congress will explore the burgeoning field of skin microbiome research, with case studies focused on topics such atopic dermatitis, psoriasis, acne, and allergy, and the microbiome-based products being developed to fight these diseases. The conference also provided insight into the future of microbiome-based cosmetics, with numerous presentations given on trial design, commercial strategy, and consumer awareness and expectations.
With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

5th Probiotics & Prebiotics Congress: USA
2020-11-05 - 2020-11-06 | San Diego, USA
This Congress will include numerous presentations on probiotics discovery and product development, as well as prebiotics, diet and nutrition. Alongside several case studies on digestive health, metabolic diseases, ageing and allergy, the conference highlighted the importance of the early life microbiome, the milk microbiome, and the use of probiotics to modulate the infant gut.
With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

3rd Annual Lab Asset & Facility Management in Pharma 2020
2020-11-10 - 2020-11-12 | Virtual Event
The 3rd Lab Asset & Facility Management in Pharma will return to Boston this Winter as your ONLY industry led meeting focusing on R&D asset and FM, enabling you to regain control of your assets, optimize your space and benchmark best practices to stay ahead of the curve.

Through strategic planning and rolling out digital tracking, Lab Asset, Operations and FM Directors are beginning to regain control of their inventory, asset value and optimize facility footprint to:

Reduce unnecessary downtime and ensure reliable business operations
Strengthen relationships and drive innovative partnership models with OEMs
Maximize asset lifecycle and value – and make informed financial decisions during purchasing, renewing, reselling and auctioning
Optimize lab and working space, implementing the ethos of shared economy within the R&D scientific community
Enhance capital efficiency to re-invest in drug development programs
Anticipate expansion from a lab and equipment perspective

Digital Neuropsychiatric Drug Development Summit
2020-11-10 - 2020-11-12 | Virtual Event
The 3rd Annual Neuropsychiatric Drug Development Summit will return in November 2020 as an interactive, virtual meeting. This definitive industry meeting is focused on helping you develop the next generation of more clinically effective therapeutics.

With an emphasis on depressive disorders, schizophrenia, addiction and PTSD, this timely meeting provides a much-needed platform for industry and academic thought leaders to:

Dive into novel therapeutic approaches for PTSD with Aptinyx, Bionomics, Tonix & MAPS
Uncover the emergence of the next generation of anti-psychotics with Karuna Therapeutics, NeuroRx & Intra-cellular Therapeutics
Explore industry approaches for innovative trial design and new methods to modelling the placebo response with Novartis, Otsuka & Yale University
Hear how pioneering biotechs are spearheading drug development for substance use disorders with Opiant Pharmaceuticals & the NIDA
Learn how to advance neurophysiology and cognition translational biomarkers and be part of the drive towards precision medicine with Takeda & UT Southwestern

Uniting 60+ drug developers from all corners of the world, Neuropsychiatric Drug Development is your opportunity to discuss in depth how to push forward the frontiers of neuropsychiatric drug development to develop the next generation of more clinically effective therapeutics.
To know more about Digital Neuropsychiatric Drug Development Summit please click here.

TIDES Europe: Oligonucleotide & Peptide Therapeutics 2020
2020-11-10 - 2020-11-13 | 100% Virtual
Europe’s #1 forum for oligonucleotide, peptide, CRISPR and mRNA therapeutic leaders to discuss scientific strategies and accelerate products to market, while also creating new successful partnerships. This year’s virtual agenda features 5 scientific tracks covering in-depth development strategies, trends and technologies across the entire oligonucleotide and peptide spectrum; as well as a partnering track that will keep you ahead of your competition, and work towards collaborations.

2nd Annual Biomarkers for Rare Non-Oncological Disorders
2020-11-10 | Digital Event
The Digital 2nd Annual Biomarkers for Rare Non-Oncological Diseases Summit will unite biopharma, diagnostic and healthcare teams to advance the application of precision medicine in rare diseases beyond oncology.
This event is completely free for Drug Developers, Researchers and Academics. To register your complimentary pass, simply follow this link: www.nononcologyraredisease-summit.com/take-part/register/
Tackling critical challenges from early research through to late-stage market access, this meeting is the must-attend summit for industry-led insights in delivering novel treatments for patients in need.
How Will it Help You Deliver Predictive Markers & Effective Drug-Dx Products?
Drawing on a multitude of disease areas spanning neurology, cardiology, metabolic, renal, inflammatory and more, the meeting combines a range of perspectives and experiences for unparalleled learning opportunities.
With 2 days of in-depth case studies, interactive panel discussions, dedicated Q+A time and valuable networking opportunities, you can walk away with improved end-to-end strategies from early biomarker validation to effective clinical trials and enabling successful regulatory, payer and commercial discussions.
Take a look at the full event guide to see all case studies, pre-conference workshop details and the full expert speaker faculty!

Microbiome Connect: Skin 2020
2020-11-10 - 2020-11-11 | Virtual Event
2019 proved to be a pivotal year for the skin microbiome, as personal care giants Unilever launched their Dove range of ‘microbiome-friendly’ skincare products. Clearly, the biggest players in beauty and personal care have recognised the potential commercial value of skin microbiome-based consumer product claims and formulations.

Moving forward into 2021, the market will continue to see more and more products launched with microbiome claims backed through next-generation sequencing techniques. Including ingestible beauty products that influence the gut-skin axis, to truly personalised skincare solutions and mass market formulations – there’s a huge commercial opportunity to commercialise skin microbiome research into consumer care products.
So, what’s different at Microbiome Connect: Skin EU Virtual?
Six new topics to explore:

The skin-gut axis and the development of ingestible beauty products.
Personalisation of skin-microbiome products and formulation considerations.
Defining skin-microbiome industry terminology and developing scientifically backed claims that resonate with consumers.
Next generation sequencing techniques and their application in claims development.
New data demonstrating the role of the microbiome in common skin conditions including acne, eczema and dandruff.
The vaginal and oral microbiomes and the mass market product development opportunities to treat gingivitis/periodontitis and sexually transmitted infections.

All tickets to tune into this event are 2FOR1 – simply quote this when booking online!

2nd Digital Exosome Based Therapeutic Development Summit
2020-11-11 - 2020-11-12 | Digital Event
The exosome therapeutics field is booming with anticipation as preparations are underway for the first few clinical trials and money pours in through partnerships and pipeline acquisitions. However, more is needed to be done to uncover more scientific knowledge, fine-tune manufacturing methods and prepare trials to meet regulatory expectations.
Considering this, the 2nd Digital Exosome Based Therapeutic Development Summit (November 11-12, 2020) will unite pharma, biotech, academic and technology providers to advance exosome therapeutics into a clinical and commercial reality.

This is your only industry-focused meeting dedicated specifically to evidence-based and regulated exosome-based therapeutics. Bringing together industry leaders and newcomers on the field, it’s two days not to be missed.
With 20+ speakers and 2 days of unrivalled in-depth content, join your peers to discuss:

End-to-end insights on drug development from discovery to scalable manufacturing of GMP-grade exosomes, clinical preparation, commercial strategy and more with Evox Therapeutics, Aruna Bio, Codiak Biosciences and ReNeuron
Innovations in exosome-based therapeutics, such as their applications in COVID-19 vaccines with Capricor Therapeutics
Understanding the underlying mechanisms of exosome interactions to inform target identification and development decisions with Scripps Research and University Hospital Essen
Preparing for clinical trials with key lessons learned from the best in the business such as Aegle Therapeutics
Over 4+ hours scheduled virtual networking time to connect with the community all from the comfort of your own home or office!

If you are exploring the therapeutic applications of exosomes in an evidence-based approach, this is the place for you.
Spanning 2 days, this digital program is tailor-made to showcase the field’s most exciting breakthroughs to inform your discovery, manufacturing, commercial and regulatory strategies. Join this interactive forum this November to drive GMP-grade manufacturing methods, consistent exosome production, improved isolation and purification, effective clinical and regulatory preparations, beneficial industry partnerships and more.
To know more about 2nd Digital Exosome Based Therapeutic Development Summit please click here.

Microbiome Connect: Human 2020
2020-11-12 | Virtual Event
Microbiome Connect: Human EU has been postponed this year due to the impacts of COVID-19. However, at Microbiome Connect, we’re committed to continue providing a platform for scientific presentations and networking opportunities for the microbiome community before we return to face-to-face again in 2021.

This November, we’ll be running a free-to-attend virtual symposium highlighting some of the latest scientific activity. Tune in for free on 12th November, 2020.
Agenda:
9.30 – 10:00 AM | Iron and the gut microbiome: an opportunity for LBPs functional during active gut inflammation
Jenny Bailey – CEO – Ferryx
10.15 – 10:40 AM | Gut-Brain axis mechanism of action and Clinical results on Hafnia alvei HA4597, a new probiotic strain for the regulation of appetite and weight management
Gregory Lambert – CEO – Targedys
10:55 – 11:20 AM | Rationally Designed Probiotic
Dr. Olaf Larsen – Senior Manager Science – Yakult Nederland B.V.
Register for free online.

4th Global Pharma R&D AI, Data Science and Informatics Summit
2020-11-16 - 2020-11-17 | London, UK
This Summit is designed to create a collaborative environment in which attendees engaged with the speakers, sponsors and other delegates in attendance. The meeting agenda has expanded to include:

AI for genomics, single-cell analysis and target validation.
AI for predicting patient response.
AI impacting clinical trials.
AI for imaging.
AI for cancer immunotherapy and neurodegenerative diseases,
Clinical informatics, data integration, management and storage,
Digital therapeutics, wearables and sensors.

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

5th Medicinal Chemistry & Protein Degradation Summit
2020-11-16 - 2020-11-17 | London, UK
This Summit will focus its attention to some of the leading issues in Medicinal Chemistry today. This year the conference has expanded its coverage on protein degradation and will have a dedicated track running across both days to explore the cutting-edge research taking place in this exciting area.
The integration of AI and machine learning into the medicinal chemistry process is tackled in another track at the meeting with numerous case studies into how this developing technology is being utilized by industry leaders including Exscientia, Insitro and Bayer. This compliments the co-located informatics and AI meeting, which can be attended at any time, and examines artificial Intelligence in other parts of the drug discovery timeline.
Finally, the conference will be looking into recent advances and case studies in phenotypic screening and novel approaches to DNA encoded libraries within a dedicated track.
With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

2nd Annual Proteome- Targeted Drug Discovery Summit – Digital Event
2020-11-16 - 2020-11-18 | Virtual Event
With about 85% of the proteome currently undrugged, accessing these targets that are, at present, extremely difficult to drug, has prevented researchers from achieving desired clinical successes.
The 2nd Proteome- Targeted Drug Discovery Summit will unite large pharma and innovative biotech, as well as key opinion leaders in academia, to develop robust structural and biochemical tools to open up the full therapeutic opportunity held within the entire proteome. Identify and validate novel druggable sites and optimize structure-guided fragment-based drug design of small molecules with improved potency, selectivity, and physio-chemical properties.

Join the leading experts from the biopharmaceutical industry and academia to enhance your existing structural, chemical and computational toolbox and explore how these innovative technologies can be uniquely employed to target the entire proteome and advance your small molecule drug discovery pipeline.
Key Reasons to Attend Include

Utilize next-generation chemical biology platforms for novel target target identification with insights from Biogen, Merck & AstraZeneca
Expand the druggable proteome through next-generation screening platforms, with insight from GSK, PhoreMost & Ribon Therapeutics
Leverage innovative chemical probes to accelerate fragment-based lead generation, with insights from Novartis & The Weizmann Institute of Science
Harness structure-based computational technologies to successfully target protein-protein interactions, with insights from RAPT Therapeutics
Give rise to novel therapeutic modalities to drug the undruggable, with insights from Silicon Therapeutics& AbbVie

To know more about 2nd Annual Proteome- Targeted Drug Discovery Summit please click here.

4th Annual Antifibrotic Drug Development Summit
2020-11-16 - 2020-11-18 | Virtual Event
Solving the Translational Drug Development Gap, From Fibrotic Mechanisms to Clinically Effective Therapeutics.
Now in its 4th year, the digital AFDD summit is the industry’s definitive guide to turning mechanistic understanding of fibrosis into clinically effective therapeutics across disease areas. With 3 days of in-depth cutting-edge case studies and the highest calibre of discussions from cross-disciplinary fibrosis heavy-weights, AFDD will bridge the current translational gap to anti-fibrotic drug development success
Join 100+ fibrosis experts at this fully digital event to build a comprehensive network with like-minded peers and hurdle your translational drug development challenges to accelerate the development of more clinically effective drugs.
To know more about 4th Annual Antifibrotic Drug Development Summit please click here.

3rd Lifecycle Management for Combination Products Summit
2020-11-16 - 2020-11-18 | Virtual Event
The 3rd Lifecycle Management for Combination Products Summit is the only dedicated meeting focusing on Lifecycle Management (LCM) and perfecting design control. This year the meeting will unite senior combination products leaders online to discuss strategies and lessons learned to help you ensure commercial competitiveness in the combination product markets. From quality and product development, to CMC and regulatory affairs, our experts speakers will help you delve into how to produce a quality and safe combination product, implications of EU MDR and the final implementation phase of post-market surveillance reporting.
To know more about 3rd Lifecycle Management for Combination Products Summit please click here.

Clinical Operations in Oncology Trials USA 2020: Virtual Conference
2020-11-17 - 2020-11-18 | Virtual Event, CA
As the industry grapples with unprecedented challenges, join us for our first ever Clinical Operations in Oncology Trials USA Virtual Experience brought to you directly in the comfort of your home! Bringing together experts from across the country to discuss the latest innovations in technology, regulatory affairs as well as discover new opportunities through adaptive approaches and methods to run successful clinical trials.

To know more about Clinical Operations in Oncology Trials USA 2020 please click here.

CRISPR 2.0
2020-11-17 - 2020-11-19 | Digital Congress
Discover the Next Generation of CRISPR Tools to Enhance Specificity, Reduce Off-Target Effects & Transform Gene Editing into a Clinical Reality
CRISPR is one of the most powerful discoveries of the last decade.
In a remarkably short space of time, ‘classic’ CRISPR-Cas9 has established itself as a reliable tool in the genomics toolbox, which leads to the question: what’s next?
CRISPR 2.0 is the industry-leading meeting dedicated to answering this question by showcasing only the latest and greatest innovations in CRISPR technology, from the potential of prime editing through to epigenome editing to treat chronic pain.
Don’t get left behind. Join leading pharma and biotech companies pioneering CRISPR-based therapeutics into the clinic and academic organizations breaking new ground in establishing novel CRISPR tools.
Join us to usher in the next generation of safe, targeted and effective genome editing.
For more information on the conference, visit https://ter.li/ok8ifs
“Thank you for having me. I have attended all CRISPR Congresses and they keep getting better” John Sundman, Past attendee, CRISPR Event Series
” I greatly enjoyed the diversity and topic coverage of the talks, thanks for putting together an excellent program!” Christina Kolodzy, Past attendee, CRISPR Event Series
“A high-quality worthwhile conference, attended by first rate professionals. I learned more than I anticipated I would” Past attendee, CRISPR Event Series

CPhI & P-MEC China Virtual Expo Connect
2020-11-18 - 2020-12-18 | Virtual Event powered by CPhI China & Pharmasources.com
As well as the physical CPhI & P-MEC China 2020 show that will take place in Shanghai from 16th – 18th December, a digital extension of the event – known as “Virtual Expo Connect” – will take place online from November 18th – December 18th, allowing you to do business in China, no matter your location. The hybrid “Virtual Expo Connect” offers an online alternative for international visitors unable to travel to the physical show in China due to travel restrictions, adding valued services and infinite opportunities to connect, learn, trade and grow.
CPhI & P-MEC China Virtual Expo Connect
A hybrid offline-2-online platform for global pharma professionals
Nov 18 – Dec 18, 2020
To know more about CPhI & P-MEC China Virtual Expo Connect please click here.

Digital Pathology & AI Congress: USA
2020-11-19 - 2020-11-20 | New York, USA, United States
This meeting has a reputation for providing an outstanding networking experience. Discover how to effectively harness gains such as reducing lab costs, improving links with other laboratories and scientists, and minimizing human error.

Topics covered on the agenda include:

How AI is being applied to primary diagnosis and clinical research.
AI for image analysis and advancements in imaging
Computational pathology and AI
Implementation: practicalities and costs
Pharma and industry case studies

With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

Women and Infant Health Microbiome Congress
2020-11-19 - 2020-11-20 | London, UK
With dedicated space in the schedule to network, this conference is the ideal forum to share knowledge and build partnerships.
Visit the event page to download the full agenda.

Digital Agenda Revealed: 9th HPAPI Summit
2020-11-19 - 2020-11-20 | Virtual Event
As the world around us evolves, we want to ensure we can still unite you and your peers in highly potent API development and manufacturing.
We are excited to have transformed the 9th HPAPI Summit into a fully digital meeting running on November 19-20.
Thanks to our dedicated speakers, we’re still able to deliver the high-quality content and networking opportunities that you need to advance your high potent strategy in your company, from development to containment to EHS and outsourcing.
And the best part? As a giving back to our long standing HPAPI community, pharma, biotech and academia can now register for free!
Solution provider rate starts from $1,259, register by August 7 to save up to $280.
Download the new digital event program here.
Here’s a glimpse at some of the expert speakers confirmed to present:

Christopher Sears, Senior Director, CMC Tarveda Therapeutics
Cornelia Rudolph, Clean Water DG Environment, European Commission
Graeme McKilligan, Lead Senior GMDP Inspector, MHRA
Mirjam Sax, Principal Site Manager, Genentech
Dave Eherts, Vice President Global EHS, Allergan
Andrew Hopkins, Director, Operation Quality, QA Audit & Compliance, AbbVie
John Roosa, Director, New Technology Development & Industrial Hygiene Engineer, Merck

Our bespoke virtual conference platform will allow you to network with industry colleagues, evaluate new suppliers and the latest technology HPAPI containment and participate in live Q&A with speakers. For more details see here.
We hope to see you there!
